Welcome to our dedicated page for Biotricity SEC filings (Ticker: BTCY), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to Biotricity Inc. (BTCY) filings with the U.S. Securities and Exchange Commission, including annual reports, quarterly reports, current reports, and registration statements. Biotricity is a Nevada‑incorporated medical technology and Technology‑as‑a‑Service (TaaS) company focused on remote monitoring, diagnostics, and chronic disease management, particularly in cardiac care.
Through its SEC filings, Biotricity discloses detailed information about its financial performance, risk factors, capital structure, and business operations. Forms such as the 10‑K and 10‑Q contain audited and interim financial statements, management’s discussion of results, and descriptions of the company’s TaaS model, recurring technology fees, and investment in AI‑driven automation and remote monitoring platforms.
Current reports on Form 8‑K document material events, such as the announcement of financial results for specific periods. For example, an 8‑K filing notes that Biotricity issued a press release regarding financial results for the period ended September 30, 2025. These filings help investors understand significant developments affecting BTCY.
Biotricity has also filed a Form S‑1 registration statement under the Securities Act of 1933. The S‑1 describes Biotricity’s corporate information, including its incorporation in Nevada, status as an emerging growth and smaller reporting company, and details of the securities being registered. It also includes extensive risk factor discussions and historical financial data.
On Stock Titan, AI‑powered tools can be used to summarize and interpret these filings, helping readers navigate lengthy documents by highlighting key sections on revenue drivers, recurring technology fees, remote monitoring initiatives, and risk disclosures. Users can review Biotricity’s regulatory history in one place, from periodic reports to registration statements and material event disclosures, and use AI‑generated insights to better understand the implications of BTCY’s SEC filings.
Biotricity Inc. reported solid third-quarter fiscal 2026 results, with revenue rising 10.2% to $4 million from $3.6 million a year earlier. The company highlighted its third consecutive quarter of positive EBITDA and net operating income, reflecting growing adoption of its remote cardiac monitoring solutions.
Gross margin improved to 81.5% from 76.4%, helped by a larger recurring technology-fee base and AI-driven efficiencies. Net loss narrowed to $1.1 million, or $0.042 per share, compared with $1.3 million, or $0.054 per share. Management also pointed to strong customer retention above 90% and ongoing international expansion.
Biotricity Inc. reported higher revenue and narrower losses but remains under significant financial strain. For the nine months ended December 31, 2025, revenue rose to $11.7 million from $10.1 million, with gross profit increasing to $9.5 million. Net loss attributable to common stockholders improved to $2.7 million from $9.9 million, reflecting lower operating expenses and reduced accretion and derivative costs.
Despite this progress, the balance sheet is highly leveraged. Total assets were $5.7 million against $38.2 million in total liabilities, producing a stockholders’ deficiency of $34.2 million and a working capital deficit of $18.8 million. Cash was only $256,357, and operating activities used $0.7 million of cash over nine months.
Management states that recurring losses, a large accumulated deficit of $142.1 million, and liquidity constraints raise substantial doubt about Biotricity’s ability to continue as a going concern. The company expects to fund operations through continued revenue growth and additional equity and debt financings, but there is no assurance it can secure sufficient capital or avoid further dilution.
Biotricity Inc. shareholder Ionic Ventures and its affiliates report updated beneficial ownership of 3,035,960 shares of common stock. This total includes 443,681 shares of common stock held by Ionic Ventures and up to 2,592,279 shares issuable upon conversion of Series B preferred stock.
The filing explains that further conversions of the preferred stock are limited by a 9.99% beneficial ownership cap in Biotricity’s certificate of designations, which restricts how many conversion shares can be counted. The ownership figures are based on 27,797,711 common shares outstanding as of December 12, 2025, and are jointly reported by Ionic Ventures, Ionic Management, Brendan O’Neil, and Keith Coulston.
Biotricity Inc. is registering up to 44,117,647 shares of common stock in a primary offering at an assumed price of $0.34 per share. The medical technology company provides remote cardiac monitoring solutions such as its FDA-cleared Bioflux and Biotres devices, a direct-to-consumer Bioheart monitor, and the Biocare disease management platform, aiming to build recurring technology-fee revenue from cardiac diagnostics and chronic care.
The company has expanded sales to 33 U.S. states and is investing in AI-driven analytics, supported in part by a $238,703 NIH grant, while partnering with major cloud providers for its cardiac AI model. However, Biotricity carries substantial financial risk, including approximately $21.1 million of indebtedness as of March 31, 2023, a cash balance of about $308,460, an accumulated deficit of $140.97 million, and a working capital deficiency of about $18.08 million as of September 30, 2025.
Auditors have expressed substantial doubt about its ability to continue as a going concern, and the company faces a Nasdaq delisting process after failing to meet the $35 million market value of listed securities requirement. The S-1 outlines numerous risks, including heavy leverage, the need for additional capital, potential dilution from preferred stock and convertible notes, reimbursement and regulatory uncertainties, intense competition in cardiac monitoring, and volatility and limited liquidity in its common stock.
Biotricity Inc. reported that it has released its financial results for the period ended September 30, 2025. The company announced these results through a press release dated November 14, 2025, which is included as Exhibit 99.1. The notice clarifies that this earnings information is being furnished under a current report and is not deemed filed for liability purposes under the securities laws unless specifically incorporated by reference elsewhere.
Ionic Ventures, LLC, Ionic Management, LLC, Brendan O’Neil, and Keith Coulston filed a Schedule 13G/A (Amendment No. 5) disclosing beneficial ownership of 2,926,171 shares of Biotricity Inc. (BTCY), representing 9.9% of the class, based on 26,567,769 shares outstanding as of August 13, 2025.
The position comprises 202,937 common shares and up to 2,723,234 shares issuable upon conversion of Series B Convertible Preferred Stock, subject to a 9.99% beneficial ownership limitation in the Certificate of Designations. As of September 30, 2025, up to 4,245,283 shares could be issuable within sixty days at an Alternate Conversion Price of $0.53, though portions are not deemed beneficially owned due to blocker and conversion notice limits. The reporting persons have shared voting and dispositive power over 2,926,171 shares and no sole power. They certify the holdings are not for the purpose of changing or influencing control.
Biotricity (BTCY) filed its quarterly report for the period ended September 30, 2025. The company grew revenue to $3,885,795 for the quarter (from $3,266,846) and $7,759,788 for the six months (from $6,468,589). Gross profit rose to $3,181,498 in the quarter, and Biotricity posted operating income of $273,819 compared with a prior-year operating loss. Net loss narrowed to $(690,913) for the quarter and $(1,362,890) year‑to‑date.
Liquidity remains tight with cash of $308,460 and total liabilities of $37,984,860, resulting in a stockholders’ deficit of $(33,412,378). Management disclosed a working capital deficiency of $18,077,790 and stated that these conditions raise substantial doubt about the company’s ability to continue as a going concern. As of November 13, 2025, there were 27,797,711 common shares outstanding, plus 160,672 exchangeable shares, equivalent to 27,958,383 voting securities.